A real world study of Upadacitinib to retrospectively assess the efficacy and safety of medically refractory patients with Crohn's disease (CD)
Latest Information Update: 25 Jul 2022
At a glance
- Drugs Upadacitinib (Primary)
- Indications Crohn's disease
- Focus Adverse reactions
Most Recent Events
- 25 Jul 2022 New trial record